ccx559
chemocentryx
['$ccxi', 'chemocentryx']
$ccxi chemocentryx reports safety results available from ongoing phase i trial of orally administered pd-l1 inhibitor, ccx559, at the 2022 american society of clinical oncology (asco) annual meeting #clinicaltrial
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft